Russia Pharma and Healthcare Sector Report 2019-2020An EMIS Insights Industry Report
EMIS is an ISI Emerging Markets Group Company Date: June 2019
Available in: English
The economy’s return to growth provided a strong impetus to the Russian healthcare sector in 2017. Healthcare expenditure grew by a robust 22% y/y, when measured in US dollar terms, the first increase in many years. However, at USD 92bn in 2017, it remains well below its pre-crisis level of over USD 145bn. The stabilization of the rouble and rising household incomes boosted domestic demand, with pharmaceutical sales growing for the first time in four years in terms of US dollars. The government’s import substitution drive is gradually reducing Russia’s dependence on imported medicines and medical equipment. The share of imported drugs in the market’s value fell to 70% in 2017 from 76% in 2013, according to data from local pharmaceutical market research company DSM Group.
This report provides a complete and detailed analysis of the pharma and healthcare sector for Russia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.
What this report allows you to do:
- Understand the key elements at play in the pharma and healthcare sector in Russia
- Access forecasts for growth in the sector
- View key data on healthcare spending and health insurance in Russia
- Crystallise the forces both driving and restraining this sector in Russia
- Build a complete perspective on sector trade, investment and employment
- Understand the competitive landscape and who the major players are
- View M&A activity and major deals
- Gain an understanding of the regulatory environment for the sector in Russia
- Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels).
See below for a complete table of report contents: